世界卫生组织急性白血病分型2016版与2008版区别

doi:10.3969/j.issn.1007-9572.2016.26.026

摘要/Abstract

摘要： 　　时隔8年世界卫生组织（WHO）对急性白血病分型进行了修改，本文介绍了WHO急性白血病分型2016版与2008版的区别，结合细胞遗传学和预后等分析了2016版对2008版进行删除或增加的原因。WHO急性白血病分型2016版能更好地结合和指导临床。为了临床医生能及时掌握最新急性白血病分型，并积极为医学创新做准备，本文比较分析WHO急性白血病分型2016版与2008版的区别。

关键词: 白血病, 世界卫生组织, 分型

Abstract: After eight years,the World Health Organization（WHO） has made amendments on the classification of acute leukemia.The differences between classification of acute leukemia by WHO in 2016 and 2008 editions are introduced in this paper.The reasons for deleting or adding contents in the 2016 edition based on the 2008 edition are analyzed in combination with cytogenetics and prognosis.The classification of acute leukemia by WHO in the 2016 edition can better combine and guide clinical practices.The differences between the classification of acute leukemia by WHO in the 2016 and 2008 editions are reviewed to help clinical doctors understand the latest types of acute leukemia and prepare for medical innovation.

Key words: Leukemia, World health organization, Classification

杨晓阳, 万梦婕, 陈方平. 世界卫生组织急性白血病分型2016版与2008版区别[J]. 中国全科医学, 2016, 19(26): 3253-3256.

YANG Xiao-yang, WAN Meng-jie, CHEN Fang-ping. Difference between the Classification of Acute Leukemia by World Health Organization in 2016 and 2008 Editions[J]. Chinese General Practice, 2016, 19(26): 3253-3256.

参考文献

［1］CAMPO E,SWERDLOW S H,HARRIS N L,et al.The 2008 WHO classification of lymphoid neoplasms and beyond:evolving concepts and practical applications ［J］.Blood,2011,117（19）:5019-5032. ［2］ARBER D A,ORAZI A,HASSERJIAN R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia ［J］.Blood,2016,127（20）:2391-2405. ［3］GROSCHEL S,SANDERS M A,HOOGENBOEZEM R,et al.A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia ［J］.Cell,2014,157（2）:369-381. ［4］KONOPLEV S,YIN C C,KORNBLAU S M,et al.Molecular characterization of de novo philadelphia chromosome-positive acute myeloid leukemia ［J］.Leuk Lymphoma,2013,54（1）:138-144. ［5］NACHEVA E P,GRACE C D,BRAZMA D,et al.Does BCR/ABL1 positive acute myeloid leukaemia exist? ［J］.Br J Haematol,2013,161（4）:541-550. ［6］MENDLER J H,MAHARRY K,RADMACHER M D,et al.RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures ［J］.J Clin Oncol,2012,30（25）:3109-3118. ［7］FALINI B,MACIJEWSKI K,WEISS T,et al.Multilineage dysplasia has no impact on biologic,clinicopathologic,and prognostic features of AML with mutated nucleophosmin（NPM1）［J］.Blood,2010,115（18）:3776-3786. ［8］BACHER U,SCHNITTGER S,MACIJEWSKI K,et al.Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML,supporting the WHO proposal to classify these patients as a unique entity ［J］.Blood,2012,119（20）:4719-4722. ［9］SCHLENK R F,TASKESEN E,VAN NORDEN Y,et al.The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA ［J］.Blood,2013,122（9）:1576-1582. ［10］WALTER R B,OTHUS M,BURNETT A K,et al.Significance of FAB subclassification of "acute myeloid leukemia,NOS" in the 2008 WHO classification:analysis of 5848 newly diagnosed patients ［J］.Blood,2013,121（13）:2424-2431. ［11］WANG S A,HASSERJIAN R P.Acute erythroleukemias,acute megakaryoblastic leukemias,and reactive mimics:a guide to a number of perplexing entities ［J］.Am J Clin Pathol,2015,144（1）:44-60. ［12］SHIMIZU H,YOKOHAMA A,HATSUMI N,et al.Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era ［J］.Eur J Haematol,2014,93（4）:297-301. ［13］DEN BOER M L,VAN SLEGTENHORST M,DE MENEZES R X,et al.A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome:a genome-wide classification study ［J］.Lancet Oncol,2009,10（2）:125-134. ［14］CLAPPIER E,GRARDEL N,BAKKUS M,et al.IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia,and distinguishes patients benefiting from pulses during maintenance therapy:results of the EORTC children’s Leukemia group study 58951 ［J］.Leukemia,2015,29（11）:2154-2161. ［15］BOER J M,MARCHANTE J R,EVANS W E,et al.BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia:a comparison between DCOG/Erasmus MC and COG/St.Jude signatures ［J］.Haematologica,2015,100（9）:e354-357. ［16］ROBERTS K G,MORIN R D,ZHANG J,et al.Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia ［J］.Cancer Cell,2012,22（2）:153-166. ［17］HUNGER S P,MULLIGHAN C G.Redefining ALL classification:toward detecting high-risk ALL and implementing precision medicine ［J］.Blood,2015,125（26）:3977-3987. ［18］ROBERTS K G,LI Y,PAYNE-TURNER D,et al.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia ［J］.N Engl J Med,2014,371（11）:1005-1015. ［19］WESTON B W,HAYDEN M A,ROBERTS K G,et al.Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia ［J］.J Clin Oncol,2013,31（25）:e413-416. ［20］HARRISON C J,MOORMAN A V,SCHWAB C,et al.An international study of intrachromosomal amplification of chromosome 21（iAMP21）:cytogenetic characterization and outcome ［J］.Leukemia,2014,28（5）:1015-1021. ［21］PATRICK K,WADE R,GOULDEN N,et al.Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol,UKALL 2003 ［J］.Br J Haematol,2014,166（3）:421-424. ［22］WOOD B L,WINTER S S,DUNSMORE K P,et al.T-Lymphoblastic Leukemia（T-ALL） shows excellent outcome,lack of significance of the Early Thymic Precursor（ETP） immunophenotype,and validation of the prognostic value of end-induction Minimal Residual Disease（MRD） in Children’s Oncology Group（COG） Study AALL0434 ［J］.Blood,2014,124（21）:1. ［23］JAIN N,LAMB A V,O’BRIEN S,et al.Early T-cell precursor acute lymphoblastic leukemia/lymphoma（ETP-ALL/LBL） in adolescents and adults:a high-risk subtype ［J］.Blood,2016,127（15）:1863-1869.

[1]	付积艺, 郑博月, 吴佳霏, 王珺, 李慧. 组蛋白去乙酰化酶抑制剂联合维奈克拉和阿扎胞苷治疗成人急性T淋巴细胞白血病的疗效及安全性研究[J]. 中国全科医学, 2026, 29(04): 483-489.
[2]	徐艳朋, 黄佩, 张平平, 罗艳, 施晓琪, 吴柳松, 陈艳, 何志旭. 急性T淋巴细胞白血病β-肾上腺素受体的表达情况及临床意义研究[J]. 中国全科医学, 2025, 28(27): 3391-3398.
[3]	孙琦, 周厚法, 李文倩, 解友邦, 王爱博. 不同海拔急性髓系白血病患者化疗前后血清及骨髓造血因子表达水平差异研究[J]. 中国全科医学, 2024, 27(14): 1716-1722.
[4]	孙宇馨, 湛浩然, 阿依夏姆·克依木, 徐婷婷. 中国农村孕妇生命质量现状及影响因素研究[J]. 中国全科医学, 2024, 27(06): 656-662.
[5]	Searle Kendall, Blashki Grant, Kakuma Ritsuko, 杨辉, 吕淑荣, 李宝琪, 肖莹莹, Minas Harry. 将WHO《心理健康差距干预指南》应用于中国全科医学服务：一项德尔菲研究[J]. 中国全科医学, 2024, 27(01): 15-26.
[6]	周文京, 赏石丽, 杨倩, 冯悦荣, 李俊. 血小板/白蛋白比值与免疫球蛋白A肾病临床和病理特征的相关性研究[J]. 中国全科医学, 2023, 26(29): 3657-3664.
[7]	陈颖, 李纪鹏, 叶佩佩. 整合流式评分在骨髓增生异常综合征中的诊断和预后价值研究[J]. 中国全科医学, 2023, 26(11): 1361-1368.
[8]	陈晓奉, 王蒙, 李忠玉, 李佳佳. Venetoclax联合化疗治疗复发/难治性急性髓系白血病的临床研究[J]. 中国全科医学, 2022, 25(08): 957-962.
[9]	毛晓燕, 周燕, 刘莉, 尹润秀, 杨春会, 崔婷婷, 方春连, 蒋鸿超, 田新. 云南地区儿童急性髓细胞白血病（非M3型）临床特征及民族差异研究[J]. 中国全科医学, 2022, 25(08): 979-983.
[10]	王伊娜, 董葆, 李欣, 邵春影, 左力, 王梅, 燕宇. 白血病肾损害患者的临床病理特征研究[J]. 中国全科医学, 2022, 25(08): 952-956.
[11]	傅雷华，葛国兴，傅佳萍，张志坚，洪攀，封蔚莹. 克拉屈滨治疗经典型毛细胞白血病致间质性肺炎一例报道并文献复习[J]. 中国全科医学, 2020, 23(8): 989-992.
[12]	党萍萍，奚悦，金婷，王冉冉，肖伟伟，梁越，赵得发，王威，张丹，滕晓春. β型甲状腺激素抵抗综合征患者临床特点分析[J]. 中国全科医学, 2020, 23(36): 4635-4640.
[13]	陆敏秋，鲍立，禇彬，石磊，高珊，项秋晴，房立娟，王宇彤，刘晰，丁月华. 地西他滨单药治疗中高危骨髓增生异常综合征和急性髓系白血病的疗效观察[J]. 中国全科医学, 2020, 23(35): 4443-4447.
[14]	赵洪斌，宋洋，黄明光，曾秋涛，缪旭东，阮张涛. 锁定钢板治疗不同Neer分型肱骨近端骨折的疗效及生物力学恢复情况的评价[J]. 中国全科医学, 2019, 22(32): 3985-3989.
[15]	王朦，贾国存，成怡冰，王海军，刘炜，郭亚琼. 青蒿虎酯对人急性髓系白血病原代细胞及其细胞株K562增殖和凋亡的影响研究[J]. 中国全科医学, 2019, 22(30): 3694-3700.